Bortezomib shows promise in reducing GVHD and reconstituting immune system in some patients

NEW ORLEANS -- A drug that has become a mainstay of multiple myeloma treatment may outperform alternative therapies in re-establishing the immune system of patients who have received stem cell transplants from unrelated, partially matched donors, according to early clinical trial results to be presented by Link:  http://www.dfci.harvard.edu

Read the whole article on Science Blog

More from Science Blog